A Phase II, Open-Label Trial Evaluating GV1001 in Advanced Hepatocellular Carcinoma.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00444782|
Recruitment Status : Completed
First Posted : March 8, 2007
Last Update Posted : December 18, 2008
Information provided by:
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Completed|
|Actual Primary Completion Date :||April 2008|
|Actual Study Completion Date :||April 2008|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Greten TF, Forner A, Korangy F, N'Kontchou G, Barget N, Ayuso C, Ormandy LA, Manns MP, Beaugrand M, Bruix J. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer. 2010 May 17;10:209. doi: 10.1186/1471-2407-10-209.